Congress of the French Society of Ophthalmology - SFO 2013

Article

SFO 2013

The Congress of the French Society of Ophthalmology (SFO) is in its 119th year. The issues tackled in the main lectures include: advances in gene therapy, macular pathologies, childhood glaucoma, corneal ulcerations and management of conjunctival melanoma. There will also be interactive surgical workshops and over 100 exhibition stands.

For more information please visit the SFO website or alternatively for a printable PDF click here

Related Videos
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
Marjorie Rah, OD, PhD, FAAO
Giulia Corradetti, MD, discusses her presentation "Functional Microperimetric Correlates of OCT Structures Features in Intermediate AMD"
Related Content
Image by Jennifer Toomey/MJH Life Sciences using Adobe Firefly AI

Reconfiguring treatment goals for paediatric myopia around ocular development

May 8th 2024
Article

Considering ages and stages of myopia progression in a therapeutic timeline

Site Logo

Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections

June 29th 2023
Podcast
A young girl undergoes an eye exam. Image credit: ©Alexis S/peopleimages.com – stock.adobe.com

ARVO 2024: Children with CVI experience lower vision-specific quality of life, study results indicate

May 6th 2024
Article

Investigators say children with cortical/cerebral visual impairment experience markedly lower vision-specific quality of life

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022
Podcast
A group of children run outside. Image credit: ©JackF – stock.adobe.com

ARVO 2024: CHAMP phase 3 trial shows myopia controlled by low-dose atropine 0.01% over 4-year course

May 5th 2024
Article

This study also investigated the development of myopia rebound when dosing was discontinued

Susana Chung, OD, PhD, talks about her ARVO presentation titled "How similar is reading with central vision loss to reading in normal peripheral vision?"

ARVO 2024: New research indicates the need for a new approach to central vision loss

May 5th 2024
Article

Susana Chung, OD, PhD, speaks about one of her ARVO presentations and the future of artificial intelligence in eye care

© 2024 MJH Life Sciences

All rights reserved.